Targeted therapy before surgery for alk-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a targeted therapy pill (called iruplinalkib) given before surgery for people with a certain type of lung cancer (ALK-positive NSCLC). The goal is to see if the pill can shrink the tumor, making it easier to remove completely during surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with non-small cell lung cancer (NSCLC)
- Your cancer is stage III or IVA (it has not spread far)
- Your tumor tests positive for a genetic change called ALK
- You are healthy enough to have surgery, and your doctors believe the tumor can be completely removed
- You have not received targeted therapy, immunotherapy, or an investigational drug for your lung cancer before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a new targeted pill (iruplaltinib) along with chemotherapy before surgery can help shrink tumors and improve outcomes for people with ALK-positive lung cancer. Participation involves taking study drugs, having tests, and then undergoing surgery.
This study tests whether taking a pill called iruplinalkib after surgery for early-stage ALK-positive lung cancer can help keep cancer from coming back. Iruplinalkib is a type of targeted therapy that blocks cancer cells with a specific ALK gene change.
This study looks at whether giving a targeted therapy pill (lorlatinib) before surgery can help shrink ALK-positive lung cancer and improve outcomes. It also aims to understand why some tumors may not respond to this treatment.
This trial tests giving targeted therapy pills before and after surgery for stage III lung cancer with certain rare gene changes. The goal is to see if this approach helps shrink or control the cancer better than surgery alone.
This study tests a combination of two targeted medicines for people with a specific type of non-small cell lung cancer (NSCLC) that has the ALK gene change. The goal is to see if giving these drugs before surgery can shrink tumors and improve outcomes.
This trial tests whether taking lorlatinib before surgery can shrink or control early-stage lung cancer that has a specific genetic change (ALK). It aims to improve surgical outcomes and reduce the chance of the cancer coming back.
Hear when a new Potentially Resectable ALK Positive Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.